Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Influenza

Free Subscription 15.04.2024 1 Antimicrob Agents Chemother 1 Arch Virol 1 BMJ 3 Epidemiol Infect 1 J Clin Microbiol 1 J Exp Med 1 J Virol 6 J Virol Methods 2 JAMA 8 Lancet 1 MMWR Morb Mortal Wkly Rep 2 N Engl J Med 2 PLoS Comput Biol 1 PLoS Med 22 PLoS One 28 Vaccine 2 Virology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Antimicrob Agents Chemother

1. CHESNOKOV A, Ivashchenko AA, Matsuzaki Y, Takashita E, et al
   Influenza C virus susceptibility to antivirals with different mechanisms of action.
   Antimicrob Agents Chemother. 2024 Apr 8:e0172723. doi: 10.1128/aac.01727.
   PubMed         Abstract available
   
   

   
   Arch Virol

2. KUTKAT O, Gomaa M, Aboulhoda BE, Moatasim Y, et al
   Genetic and virological characteristics of a reassortant avian influenza A H6N1 virus isolated from wild birds at a live-bird market in Egypt.
   Arch Virol. 2024;169:95.
   PubMed         Abstract available
   
   

   
   BMJ

3. LOOI MK
   Bird flu: Person with rare strain in US sparks alarm about cow transmission.
   BMJ. 2024;385:q797.
   PubMed        
   
   

   
   Epidemiol Infect

4. LOZANO D, Dohoo C, Elfstrom D, Carswell K, et al
   COVID-19 outbreak at a residential apartment building in Northern Ontario, Canada.
   Epidemiol Infect. 2024;152:e53.
   PubMed         Abstract available
   
   
5. TSANG TK, Du RQR, Fang VJ, Lau EHY, et al
   Decreased risk of non-influenza respiratory infection after influenza B virus infection in children.
   Epidemiol Infect. 2024 Apr 8:1-21. doi: 10.1017/S0950268824000542.
   PubMed        
   
   
6. NESTERUK I
   Should we ignore SARS-CoV-2 disease?
   Epidemiol Infect. 2024;152:e57.
   PubMed         Abstract available
   
   

   
   J Clin Microbiol

7. PARK SY, Faraci G, Ward P, Lee HY, et al
   Utilizing cost-effective portable equipment to enhance COVID-19 variant tracking both on-site and at a large scale.
   J Clin Microbiol. 2024;62:e0155823.
   PubMed         Abstract available
   
   

   
   J Exp Med

8. WU TT, Travaglini KJ, Rustagi A, Xu D, et al
   Interstitial macrophages are a focus of viral takeover and inflammation in COVID-19 initiation in human lung.
   J Exp Med. 2024;221:e20232192.
   PubMed         Abstract available
   
   

   
   J Virol

9. BU H, Zhang S, Li P, Liu Z, et al
   Secreted phospholipase PLA2G2E contributes to regulation of T cell immune response against influenza virus infection.
   J Virol. 2024 Apr 9:e0019824. doi: 10.1128/jvi.00198.
   PubMed         Abstract available
   
   

   
   J Virol Methods

10. SUZUKI R, Kamiyama A, Ito H, Kawashiro K, et al
    The development of a rapid, high-throughput neutralization assay using a SARS-CoV-2 reporter.
    J Virol Methods. 2024;326:114894.
    PubMed         Abstract available
    
    
11. FERNANDEZ-SANCHEZ F, Martin-Bautista E, Rivas-Ruiz F, Wu W, et al
    Evaluation of the EasyNAT SARS-CoV-2 assay PCR test for the diagnosis of SARS-CoV-2 infection.
    J Virol Methods. 2024;326:114908.
    PubMed         Abstract available
    
    
12. BOESELT T, Terhorst P, Kroenig J, Nell C, et al
    Specific molecular peak analysis by ion mobility spectrometry of volatile organic compounds in urine of COVID-19 patients: A novel diagnostic approach.
    J Virol Methods. 2024;326:114910.
    PubMed         Abstract available
    
    
13. KATSUNO T, Kimura M, Terada-Hirashima J, Kazuyama Y, et al
    Diagnostic accuracy of direct reverse transcription-polymerase chain reaction using guanidine-based and guanidine-free inactivators for SARS-CoV-2 detection in saliva samples.
    J Virol Methods. 2024;326:114909.
    PubMed         Abstract available
    
    
14. LEE SS, Kim AL, Park JH, Lee DH, et al
    Optimization of duplex digital PCR for the measurement of SARS-CoV-2 RNA.
    J Virol Methods. 2024;326:114911.
    PubMed         Abstract available
    
    
15. BANG LL, Tornby DR, Pham STD, Assing K, et al
    Culturing of SARS-CoV-2 from patient samples: Protocol for optimal virus recovery and assessment of infectious viral load.
    J Virol Methods. 2024;326:114912.
    PubMed         Abstract available
    
    

    
    JAMA

16. NIELSEN FM, Klitgaard TL, Siegemund M, Laake JH, et al
    Lower vs Higher Oxygenation Target and Days Alive Without Life Support in COVID-19: The HOT-COVID Randomized Clinical Trial.
    JAMA. 2024 Mar 19:e242934. doi: 10.1001/jama.2024.2934.
    PubMed         Abstract available
    
    
17. SCHWARTZSTEIN RM
    Oxygen Supplementation in COVID-19-How Much Is Enough?
    JAMA. 2024 Mar 19. doi: 10.1001/jama.2024.2935.
    PubMed        
    
    

    
    Lancet

18. NARASARAJU T, Ravi Y, Jonsson CB, Chow VTK, et al
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1338-1339.
    PubMed        
    
    
19. SORAAS A, Brunvoll SH, Nygaard AB, Dahl JA, et al
    Post-COVID-19 condition symptoms 6-12 months after hospitalisation in Wuhan.
    Lancet. 2024;403:1336.
    PubMed        
    
    
20. PETO L, Basnyat B, Horby P
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial - Authors' reply.
    Lancet. 2024;403:1339-1340.
    PubMed        
    
    
21. HSU NC, Tokuda Y
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1338.
    PubMed        
    
    
22. GU X, Huang L, Zhang H, Cao B, et al
    Post-COVID-19 condition symptoms 6-12 months after hospitalisation in Wuhan - Authors' reply.
    Lancet. 2024;403:1336-1337.
    PubMed        
    
    
23. BHUSAL S, Adhikari S
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1339.
    PubMed        
    
    
24. MCEVOY N, Lowry J, O'Dowd A, Curley GF, et al
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1337.
    PubMed        
    
    
25. HASHIM Z, Nath A, Tripathy NK
    High-dose corticosteroid therapy in COVID-19: the RECOVERY trial.
    Lancet. 2024;403:1337-1338.
    PubMed        
    
    

    
    MMWR Morb Mortal Wkly Rep

26. EL KALACH R, Jones-Jack N, Elam MA, Olorukooba A, et al
    Federal Retail Pharmacy Program Contributions to Bivalent mRNA COVID-19 Vaccinations Across Sociodemographic Characteristics - United States, September 1, 2022-September 30, 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:286-290.
    PubMed         Abstract available
    
    

    
    N Engl J Med

27. GANDHI RT, Hirsch M
    Treating Acute Covid-19 - Final Chapters Still Unwritten.
    N Engl J Med. 2024;390:1234-1236.
    PubMed        
    
    
28. HAMMOND J, Fountaine RJ, Yunis C, Fleishaker D, et al
    Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.
    N Engl J Med. 2024;390:1186-1195.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

29. SHAO Y, Magee AF, Vasylyeva TI, Suchard MA, et al
    Scalable gradients enable Hamiltonian Monte Carlo sampling for phylodynamic inference under episodic birth-death-sampling models.
    PLoS Comput Biol. 2024;20:e1011640.
    PubMed         Abstract available
    
    
30. ATAMER BALKAN B, Chang Y, Sparnaaij M, Wouda B, et al
    The multi-dimensional challenges of controlling respiratory virus transmission in indoor spaces: Insights from the linkage of a microscopic pedestrian simulation and SARS-CoV-2 transmission model.
    PLoS Comput Biol. 2024;20:e1011956.
    PubMed         Abstract available
    
    

    
    PLoS Med

31. ELIGULASHVILI A, Gordon M, Lee JS, Lee J, et al
    Long-term outcomes of hospitalized patients with SARS-CoV-2/COVID-19 with and without neurological involvement: 3-year follow-up assessment.
    PLoS Med. 2024;21:e1004263.
    PubMed         Abstract available
    
    

    
    PLoS One

32. LI Z, Deng X, Mao Y, Duan J, et al
    Study on the temporal and spatial relationship between public health events and the development of air transport scale: A case of the Southwest China.
    PLoS One. 2024;19:e0301461.
    PubMed         Abstract available
    
    
33. SU X, Wang S
    The impact and management of internet-based public opinion dissemination during emergencies: A case study of Baidu News during the first wave of coronavirus disease 2019 (COVID-19).
    PLoS One. 2024;19:e0299374.
    PubMed         Abstract available
    
    
34. MARCHANT E, Dowd J, Bray L, Rowlands G, et al
    The well-being and work-related stress of senior school leaders in Wales and Northern Ireland during COVID-19 "educational leadership crisis": A cross-sectional descriptive study.
    PLoS One. 2024;19:e0291278.
    PubMed         Abstract available
    
    
35. MO PKH, Xin M, Wang Z, Lau JTF, et al
    Patterns of sex behaviors and factors associated with condomless anal intercourse during the COVID-19 pandemic among men who have sex with men in Hong Kong: A cross-sectional study.
    PLoS One. 2024;19:e0300988.
    PubMed         Abstract available
    
    
36. BRINKLEY A, Sandercock G, Lowry R, Freeman P, et al
    What determines participation in sport for older adults in England: A multilevel analysis of Active Lives data.
    PLoS One. 2024;19:e0301790.
    PubMed         Abstract available
    
    
37. FISMAN DN, Amoako A, Simmons A, Tuite AR, et al
    Impact of immune evasion, waning and boosting on dynamics of population mixing between a vaccinated majority and unvaccinated minority.
    PLoS One. 2024;19:e0297093.
    PubMed         Abstract available
    
    
38. ZIESEL A, Jabbari H
    Unveiling hidden structural patterns in the SARS-CoV-2 genome: Computational insights and comparative analysis.
    PLoS One. 2024;19:e0298164.
    PubMed         Abstract available
    
    
39. SHARAN M, Sakthivel M, Rubeshkumar P, Nagarajan R, et al
    Face mask use in the city of Chennai, India: Results from three serial cross-sectional surveys, 2021.
    PLoS One. 2024;19:e0297909.
    PubMed         Abstract available
    
    
40. SAMSON S, Lord E, Makarenkov V
    Assessing the emergence time of SARS-CoV-2 zoonotic spillover.
    PLoS One. 2024;19:e0301195.
    PubMed         Abstract available
    
    
41. OZSAHIN DU, Isa NA, Uzun B, Ozsahin I, et al
    Quantifying holistic capacity response and healthcare resilience in tackling COVID-19: Assessment of country capacity by MCDM.
    PLoS One. 2024;19:e0294625.
    PubMed         Abstract available
    
    
42. STACEVICIENE I, Ivaskeviciene I, Burokiene S, Steponaviciene A, et al
    Epidemiological changes of acute respiratory infections in children: A single-center experience after COVID-19 lockdown.
    PLoS One. 2024;19:e0300877.
    PubMed         Abstract available
    
    
43. FUJII D, Nakata T, Ojima T
    Heterogeneous risk attitudes and waves of infection.
    PLoS One. 2024;19:e0299813.
    PubMed         Abstract available
    
    
44. LI B, Xu Y, Wang Y, Zhang B, et al
    DECTNet: Dual Encoder Network combined convolution and Transformer architecture for medical image segmentation.
    PLoS One. 2024;19:e0301019.
    PubMed         Abstract available
    
    
45. THERESA POOL SN, Shroff EH, Chetty A, Lewis L, et al
    Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population.
    PLoS One. 2024;19:e0299747.
    PubMed         Abstract available
    
    
46. MWANGI LW, Omuse G, Adam R, Ong'ete G, et al
    Post-vaccination SARS-CoV-2 IgG spike antibody responses among clinical and non-clinical healthcare workers at a tertiary facility in Kenya.
    PLoS One. 2024;19:e0299302.
    PubMed         Abstract available
    
    
47. ANDERSEN KM, Khan FL, Park PW, Wiemken TL, et al
    Using a data-driven approach to define post-COVID conditions in US electronic health record data.
    PLoS One. 2024;19:e0300570.
    PubMed         Abstract available
    
    
48. MASHA'AL D, Rababa M, Hayajneh A, Shahrour G, et al
    The mediating role of emotional intelligence on nursing students' coping strategies and anxiety during the COVID-19 pandemic.
    PLoS One. 2024;19:e0300057.
    PubMed         Abstract available
    
    
49. HERNANDEZ-BELLO J, Lorenzo-Leal AC, Munoz-Valle JF, Morales-Nunez JJ, et al
    Neutralizing antibody responses to the Delta variant of SARS-CoV-2 following vaccination with Ad5-nCoV (CanSino) in the Mexican population.
    PLoS One. 2024;19:e0299520.
    PubMed         Abstract available
    
    
50. WANG Y, Yuan F, Song Y, Rao H, et al
    Prediction of cross-border spread of the COVID-19 pandemic: A predictive model for imported cases outside China.
    PLoS One. 2024;19:e0301420.
    PubMed         Abstract available
    
    
51. LIEBERTHAL B, Jackson S, de Urioste-Stone S
    Risk perceptions and behaviors concerning rural tourism and economic-political drivers of COVID-19 policy in 2020.
    PLoS One. 2024;19:e0299841.
    PubMed         Abstract available
    
    
52. CASSUM LA, Lakhani A, Sachwani S, Salim Z, et al
    Beyond the classroom walls: Stakeholder experiences with remote instruction in Post RN baccalaureate nursing program during the COVID-19 pandemic: A qualitative inquiry.
    PLoS One. 2024;19:e0300007.
    PubMed         Abstract available
    
    
53. ALAMARES-SAPUAY J, Kishko M, Lai C, Parrington M, et al
    Mutations in the F protein of the live-attenuated respiratory syncytial virus vaccine candidate DeltaNS2/Delta1313/I1314L increase the stability of infectivity and content of prefusion F protein.
    PLoS One. 2024;19:e0301773.
    PubMed         Abstract available
    
    

    
    Vaccine

54. AKMATOVA R, Ebama MS, Temirbekov S, Alymkulova V, et al
    A comparative analysis of knowledge, attitude, and practice (KAP) towards influenza and influenza vaccination among healthcare workers in Kyrgyzstan prior to and during the COVID-19 pandemic.
    Vaccine. 2024 Apr 9:S0264-410X(24)00420-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
55. ZURCHER SJ, Signorell A, Lechot-Huser A, Aebi C, et al
    Childhood vaccination coverage and regional differences in Swiss birth cohorts 2012-2021: Are we on track?
    Vaccine. 2023;41:7226-7233.
    PubMed         Abstract available
    
    
56. CHARD AN, Machingaidze C, Loayza S, Gharpure R, et al
    Estimating averted illnesses from influenza vaccination for children and pregnant women - El Salvador, Panama, and Peru, 2011-2018.
    Vaccine. 2024 Apr 6:S0264-410X(24)00419-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
57. WU CY, Kao SE, Tseng YC, Hou JT, et al
    Pilot-scale production of a highly efficacious and stable monoglycosylated influenza split virus vaccine.
    Vaccine. 2024;42:2220-2228.
    PubMed         Abstract available
    
    
58. MOFFETT KW, Seserman K, Margolis KA, Kranzler EC, et al
    Differences in social media use by COVID-19 vaccination status.
    Vaccine. 2024 Mar 20:S0264-410X(24)00318-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
59. SASI A, Dandotiya J, Kaushal J, Ganguly S, et al
    Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA vaccines in adolescent/young adults with cancer: A prospective cohort study.
    Vaccine. 2024 Mar 20:S0264-410X(24)00329-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
60. SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Durocher Y, et al
    CHO cells for virus-like particle and subunit vaccine manufacturing.
    Vaccine. 2024 Mar 18:S0264-410X(24)00321-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
61. CAMPAGNA R, Dominelli F, Zingaropoli MA, Ciurluini F, et al
    COVID-19 vaccination in cancer patients: Immune responses one year after the third dose.
    Vaccine. 2024 Mar 17:S0264-410X(24)00304-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
62. FIX J, Christopher Mast T, Smith K, Baker N, et al
    Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
    Vaccine. 2024 Mar 16:S0264-410X(24)00323-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
63. COTTON SA, Subramanian A, Hughes TD, Huang Y, et al
    The effect of SARS-COV-2 variant on non-respiratory features and mortality among vaccinated and non-fully vaccinated patients.
    Vaccine. 2024 Mar 14:S0264-410X(24)00195-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
64. CAMERON DB, Grage L, Van Wyck R, Edwards A, et al
    Identifying trusted local sources and predicting behavior change pathways according to COVID-19 vaccination status: Results of a 2022 statewide survey of Alaskan adults.
    Vaccine. 2024 Mar 14:S0264-410X(24)00314-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
65. EL SALIBI N, Abdulrahim S, El Haddad M, Abi Zeid B, et al
    Predicting intention to vaccinate against COVID-19 in older Syrian refugees in Lebanon: Findings from a multi-wave study.
    Vaccine. 2024 Mar 13:S0264-410X(24)00213-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
66. MCCOSKER LK, Ware RS, Seale H, Hooshmand D, et al
    The effect of a financial incentive on COVID-19 vaccination uptake, and predictors of uptake, in people experiencing homelessness: A randomized controlled trial.
    Vaccine. 2024 Mar 13:S0264-410X(24)00307-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
67. RUSS S, Myers C, Licherdell E, Bowden A, et al
    Sociodemographic and Occupational Characteristics Associated with Early and Continued COVID-19 Vaccine Uptake Among Healthcare Personnel: Monroe County, NY.
    Vaccine. 2024 Mar 12:S0264-410X(24)00306-2. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
68. SHIJIA YAN A, Jay Sehgal N
    Partisan divide and Racial/Ethnic disparities in COVID-19 vaccine hesitancy among Parents/Guardians and vaccine uptake among children in the U.S.
    Vaccine. 2024 Mar 11:S0264-410X(24)00309-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
69. MORO PL, Carlock G, Fifadara N, Habenicht T, et al
    Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
    Vaccine. 2024 Mar 9:S0264-410X(24)00262-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
70. SU YW, Qiu YZ, Wang YH, Xu Y, et al
    Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
    Vaccine. 2024 Mar 8:S0264-410X(24)00277-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
71. LASRADO N, Rossler A, Rowe M, Collier AY, et al
    Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1.
    Vaccine. 2024;42:2117-2121.
    PubMed         Abstract available
    
    
72. MENG L, Harris L, Shaw L, Lymon H, et al
    Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged >/= 12 years, United States, August 2021-October 2
    Vaccine. 2024 Mar 6:S0264-410X(24)00271-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
73. KARRAS J, Harrison M, Steffens M, Abdi I, et al
    "COVID is a huge jigsaw puzzle that I am trying to make sense of myself": Exploring the perceptions towards the COVID-19 vaccine communication strategy in Australia amongst unvaccinated Australian adults.
    Vaccine. 2024 Mar 6:S0264-410X(24)00276-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
74. WONG WHS, Leung DL, Yip KM, So HK, et al
    Effectiveness of inactivated COVID-19 vaccine CoronaVac in children aged less than 3 years old during Omicron wave in Hong Kong.
    Vaccine. 2024 Mar 6:S0264-410X(24)00226-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
75. CHEN D, Cowling BJ, Ainslie KEC, Lin Y, et al
    Association of COVID-19 vaccination with duration of hospitalization in older adults in Hong Kong.
    Vaccine. 2024 Mar 5:S0264-410X(24)00252-4. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
76. RAETHKE M, van Hunsel F, Luxi N, Lieber T, et al
    Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study.
    Vaccine. 2024 Mar 6:S0264-410X(24)00273-1. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
77. YASHAR-GERSHMAN SG, Rosenberg AT, Sawhney M, Fernanda Machicao M, et al
    Developing a novel screening tool to address pediatric COVID-19 vaccine hesitancy at point of care.
    Vaccine. 2024 Mar 1:S0264-410X(24)00228-7. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
78. KOHLI M, Maschio M, Lee A, Igarashi A, et al
    Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine.
    Vaccine. 2024 Feb 29:S0264-410X(24)00117-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
79. MORGAN HJ, Clothier HJ, Sepulveda Kattan G, Boyd JH, et al
    Acute disseminated encephalomyelitis and transverse myelitis following COVID-19 vaccination - A self-controlled case series analysis.
    Vaccine. 2024 Feb 12:S0264-410X(24)00126-9. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    
80. PLUMB ID, Briggs Hagen M, Wiegand R, Dumyati G, et al
    Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among U.S. Healthcare personnel, September 2022-May 2023.
    Vaccine. 2023 Nov 14:S0264-410X(23)01287-2. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
    
81. FAKSOVA K, Walsh D, Jiang Y, Griffin J, et al
    COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals.
    Vaccine. 2024 Feb 12:S0264-410X(24)00127-0. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available
    
    

    
    Virology

82. ZHENG X, Yang R, Zhao Y, Zhang Y, et al
    Alum/CpG adjuvant promotes immunogenicity of inactivated SARS-CoV-2 Omicron vaccine through enhanced humoral and cellular immunity.
    Virology. 2024;594:110050.
    PubMed         Abstract available
    
    
83. NGUYEN CT, Nakayama M, Ishigaki H, Kitagawa Y, et al
    Increased expression of CD38 on endothelial cells in SARS-CoV-2 infection in cynomolgus macaques.
    Virology. 2024;594:110052.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.